NOAH Compendium

Printed from NOAH Compendium (http://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2021. All Rights Reserved.
Date: Monday, September 20, 2021 19:24

Release 2.149
Carprieve 100 mg Tablets for Dogs
 
Species: Dogs
Therapeutic indication: Pharmaceuticals: Anti-inflammatory preparations: Oral: Other NSAIDs
Active ingredient: Carprofen
Product:Carprieve 100 mg Tablets for Dogs
Product index: Carprieve Tablets 100 mg
Qualitative and quantitative composition
Active Ingredients :
Carprofen
100 mg
Excipients:
Tartrazine (E102)
1.2 mg
For a full list of excipients, see section Pharmaceutical Particulars
Pharmaceutical form
Tablet.
A yellow circular tablet of 8 mm diameter, 100 embossed on one side and a single breakline on the other side.
Clinical particulars
Target Species
Dogs
Indications for use, specifying the target species
In the dog:
Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post operative pain.
Contraindications
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in puppies less than 4 months of age.
Do not use in animals with known hypersensitivity to the active substance or to any of the excipients.”
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.
Special warnings for each target species
Refer to Sections, "Contraindications" and "Special precautions for use"
Special precautions for use
Special precautions for use in animals
Use in aged dogs may involve additional risk.
If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Refer to section, "Interaction with other medicinal products and other forms of interaction"
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet.
Wash hands after handling the product.
Adverse reactions (frequency and seriousness)
Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.
As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
Use during pregnancy, lactation or lay
Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.
Interaction with other medicinal products and other forms of interaction
Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Concurrent administration of potential nephrotoxic drugs should be avoided.
Amounts to be administered and administration route
For oral administration.
4 mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.
Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.
Do not exceed the stated dose.
To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable Carprofen product may be followed with Carprofen Tablets at 4 mg/kg/day for up to 5 days.
Return any halved tablets to the original pack and use at the next administration.
Any halved tablets remaining after the last administration of the product must be discarded.
Overdose (symptoms, emergency procedures, antidotes), if necessary
Do not exceed the stated dose. There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.
Withdrawal Period(s)
Not applicable.
Pharmacological particulars
Pharmacotherapeutic group: Non-steroidal anti-inflammatory drug
ATC Vet Code : QM01AE91

Pharmacodynamic properties
Carprofen, (±)-6-chloro-α-methylcarbazole-2-acetic acid, is a non-steroidal anti-inflammatory drug (NSAID). It is a derivative of phenylpropionic acid and a member of the arylpropionic acid class of NSAIDs. As a representative of the 2-arylpropionic family, it contains a chiral center at C2 of the propionic moiety and therefore, exists in 2 sterioisomeric forms, the (+)-S and (-)-R enantiomers.
Carprofen possess anti-inflammatory, anaglesic and anti-pyretic activity. Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. The precise mode of action of carprofen is not clear.
Pharmacokinetic properties
Absorption is rapid with >90% absorption after oral administration. The volume of distribution is small and carprofen is highly bound to plasma proteins. Biotransformation of carprofen occurs in the liver to form the ester glucuronide and two 1-O-acyl-β-D-glucuronide diastereoisomers. These are secreted in the biliary tract and excreted in the faeces. The Cmax is 28.51 µg/ml and the AUC is 237.33 µg/ml.hour.
Pharmaceutical particulars
List of excipients
Tartrazine (E102)
Microcrystalline cellulose
Lactose monohydrate
Croscarmellose sodium
Povidone K 30
Sodium laurilsulphate
Magnesium stearate
Incompatibilities
Not applicable.
Shelf-life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years
Special precautions for storage
Do not store above 25°C.
Store in a dry place.
Protect from light.
Nature and composition of immediate packaging
Carprieve 100mg Tablets are supplied in either:
Polypropylene Snap Secure Tubs containing 14, 30 or 100 tablets, sealed with a white low density Polyethylene Snap Secure Cap, or
Aluminium-Aluminium blister strips of 10 tablets in cartons containing 10, 20, 30, 50, 60, 70, 100, 140, 180, 200, 250, 280, 300, 500 or 1000 tablets.
Special precautions for the disposal of unused veterinary medicinal products or waste materials
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
Norbrook Laboratories Limited, Station Works, Camlough Road, NEWRY, Co. Down, BT35 6JP Northern Ireland
Marketing Authorisation Number
Vm 02000/4283
Significant changes
Date of the first authorisation or date of renewal
21 July 2009
Date of revision of the text
June 2014
Any other information
Nil.
Legal category
Legal category: POM-V
GTIN
GTIN description:Carprieve 100mg Tablets (100 Pack)
GTIN:5023534009160